

## Addendum

## Addendum: Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates

**Magdalena Cybula<sup>1</sup> and Magdalena Bieniasz<sup>1</sup>**

<sup>1</sup>Oklahoma Medical Research Foundation, Aging and Metabolism Research Program, Oklahoma City, OK 73104, USA

**Published:**

**Copyright:** © 2023 Cybula and Bieniasz. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has an addendum:** No funding was used for this publication.

Original article: Oncotarget. 2022; 13:553–575. <https://doi.org/10.18632/oncotarget.28220>